Peginterferon alfa 2a inj kit 180 mcg 0 5ml
Common Questions and Answers about Peginterferon alfa 2a inj kit 180 mcg 0 5ml
pegasys
Need more info on medical condition to truly answer, obviously you have elevated liver functions, do you have hep c ?
Direct hyperbilirubinemia was also more frequent with peginterferon lambda vs peginterferon alfa-2a. Indeed, 4 patients discontinued peginterferon lambda as a result of elevated bilirubin vs 0 patients receiving peginterferon alfa-2a. After discontinuing or reducing the dose of peginterferon lambda, bilirubin levels decreased rapidly.
5 µg/kg/week plus ribavirin 800-1400 mg/day, peginterferon alfa-2b 1.0 µg/kg/week plus ribavirin 800-1400 mg/day, or peginterferon alfa-2a 180 µg/week plus ribavirin 1000-1200 mg/day. Ribavirin was dosed according to 4 weight categories. Patients aged 18-70 years were included, but patients weighing ≥ 125 kg, those with severe depression, or those with decompensated cirrhosis were excluded.
These results are similar to those seen with the 48-week treatment regimen of VICTRELIS added to peginterferon alfa-2b and ribavirin in HCV RESPOND-2, a pivotal Phase III study. Taken together, these studies showed that VICTRELIS combined with either peginterferon alfa-2a or alfa-2b and ribavirin achieved significantly higher SVR rates in chronic HCV genotype 1 patients who failed prior therapy compared to peginterferon and ribavirin alone.
1 ratio to one of two INCIVEK combination treatment groups (with and without a Peg-IFN-alfa-2a/RBV lead-in) or a control group. The T12/PR48 group received INCIVEK and Peg-IFN-alfa-2a/RBV for 12 weeks (without a lead-in), followed by placebo and Peg-IFN-alfa-2a/RBV for 4 weeks, followed by Peg-IFN-alfa-2a/RBV for 32 weeks.
Thirteen patients with HBeAg-negative CHB received peginterferon alfa-2a (180 microg/week) for 60 wk or peginterferon alfa-2a (180 microg/week) for 12 wk followed by 48 wk of peginterferon alfa-2a plus lamivudine.
WEEK 28 INTERIM ANALYSIS
M. Shiffman1, A. Ahmed2, I. Jacobson3, R. Pruitt4, E.
[24] Therefore, it is the recommendation of this author to reduce ribavirin stepwise by 200 mg every 2-4 weeks until adverse events either resolve or are tolerable. Peginterferon alfa-2a can be reduced from 180 to 135 µg/week and peginterferon alfa-2b from 1.5 to 1.0 µg/kg/week. Neither peginterferon alfa nor ribavirin dosing should be interrupted unless the adverse event is particularly severe and there is a concern for patient safety.
[24] Therefore, it is the recommendation of this author to reduce ribavirin stepwise by 200 mg every 2-4 weeks until adverse events either resolve or are tolerable. Peginterferon alfa-2a can be reduced from 180 to 135 µg/week and peginterferon alfa-2b from 1.5 to 1.0 µg/kg/week. Neither peginterferon alfa nor ribavirin dosing should be interrupted unless the adverse event is particularly severe and there is a concern for patient safety.
A total of 1050 previous nonresponders to peginterferon alfa/ribavirin were randomized to long-term therapy with low-dose peginterferon alfa-2a (90 µg/week) or no treatment. Primary outcomes assessed at 3.5 years included death, hepatic decompensation, the development of hepatocellular carcinoma, and histologic fibrosis progression in patients who were noncirrhotic at baseline.
Lamivudine for 52 weeks versus placebo increased HBeAg loss at 16 weeks off therapy. HBeAg loss at 24 weeks post treatment was greater after peginterferon alfa-2a versus lamivudine.
HBeAg seroconversion was assessed in 36 studies. Lamivudine or adefovir increased HBeAg seroconversion versus placebo. Interferon alfa-2b64,83 increased post-treatment seroconversion. Lamivudine monotherapy failed to sustain seroconversion.
We conducted a randomized controlled trial of peginterferon alfa-2a (90 mcg per week) for 3.5 years vs. no treatment in pts with chronic hepatitis C and advanced fibrosis who were nonresponders to prior therapy with peginterferon and ribavirin.
Recommended
